 |
|
A Multivalent Conjugate Vaccine for Prevention of Meningococcal Disease in Infants
Lee H. Harrison, MD
JAMA. 2008;299(2):217-219.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Major progress has been made in the development of meningococcal vaccines in the past few years. Monovalent serogroup C conjugate vaccines, shown to be immunogenic and effective in infants, have dramatically decreased the incidence of serogroup C disease in the countries in which they have been used.1-4 This reduction has occurred among those immunized and, through a decrease in pharyngeal carriage of serogroup C Neisseria meningitidis, also among the unimmunized population.5-6 These vaccines do not cover serogroup Y strains, an important cause of meningococcal disease across all age groups in the United States, including infants, and are not licensed in the United States. A new tetravalent (serogroups A, C, W-135, and Y) conjugate vaccine licensed for 2- to 55-year-olds is now recommended for all US adolescents, as well as other high-risk groups.7 This recommendation was based on the fact that US adolescents were found to have . . . [Full Text of this Article]
Author Affiliation: Lee H. Harrison, MD, Infectious Diseases Epidemiology Research Unit, University of Pittsburgh, Pittsburgh, Pennsylvania.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants: A Randomized Controlled Trial
Matthew D. Snape, Kirsten P. Perrett, Karen J. Ford, Tessa M. John, David Pace, Ly-Mee Yu, Joanne M. Langley, Shelley McNeil, Peter M. Dull, Francesca Ceddia, Alessandra Anemona, Scott A. Halperin, Simon Dobson, and Andrew J. Pollard
JAMA. 2008;299(2):173-184.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A New Tetravalent Meningococcal Vaccine for Infants
Rathore
AAP Grand Rounds 2008;19:38-39.
FULL TEXT
|
